Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

Patent metadata

Field	Value
Publication number	US-11071726-B2
Application number	US-201716346436-A
Country	US
Kind code	B2
Filing date	Nov 1, 2017
Priority date	Nov 2, 2016
Publication date	Jul 27, 2021
Grant date	Jul 27, 2021

Abstract

Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of gastric cancer, including treatment of patients diagnosed with previously untreated gastric cancer. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.

First claim

The invention claimed is:

1. A method of treating gastric cancer in a human patient who has not previously received an antineoplastic agent to treat the gastric cancer, the method comprising administering an antineoplastic therapy to the patient once every two weeks, the antineoplastic therapy consisting of:
a) 50 or 55 mg/m 2 ±5% of liposomal irinotecan,
b) 60, 70, or 85 mg/m 2 ±5% oxaliplatin,
c) 200 mg/m 2 of the (l)-form of leucovorin or 400 mg/m 2 of the (l+d) racemic form of leucovorin, and
d) 2,400 mg/m 2 5-fluorouracil;

to treat the gastric cancer in the human patient.

2. The method of claim 1 , wherein 50 mg/m 2 ±5% of liposomal irinotecan is administered to the patient during the antineoplastic therapy once every two weeks.

3. The method of claim 1 , wherein 55 mg/m 2 ±5% liposomal irinotecan is administered to the patient during the antineoplastic therapy once every two weeks.

4. The method of claim 1 , wherein 60 mg/m 2 ±5% oxaliplatin is administered to the patient during the antineoplastic therapy once every two weeks.

5. The method of claim 1 , wherein 70 mg/m 2 ±5% oxaliplatin is administered to the patient during the antineoplastic therapy once every two weeks.

6. The method of claim 1 , wherein 85 mg/m 2 ±5% oxaliplatin is administered to the patient during the antineoplastic therapy once every two weeks.

7. The method of claim 1 , wherein 50 mg/m 2 ±5% of liposomal irinotecan and 60 mg/m 2 ±5% oxaliplatin is administered to the patient during the antineoplastic therapy once every two weeks.

8. The method of claim 1 , wherein 55 mg/m 2 ±5% of liposomal irinotecan and 70 mg/m 2 ±5% oxaliplatin is administered to the patient during the antineoplastic therapy once every two weeks.

9. The method of claim 1 , wherein 50 mg/m 2 ±5% of liposomal irinotecan and 85 mg/m 2 ±5% oxaliplatin is administered to the patient during the antineoplastic therapy once every two weeks.

10. The method of claim 1 , wherein each administration of the oxaliplatin begins 2 hours after completing each administration of the liposomal irinotecan.

11. The method of claim 1 , wherein the leucovorin is administered immediately prior to the 5-fluorouracil and wherein the 5-fluorouracil is administered as an infusion over 46 hours.

12. The method of claim 1 , wherein the liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin are administered on days 1 and 15 of a 28-day treatment cycle.

13. The method of claim 1 , wherein the liposomal irinotecan is administered as an infusion over a total of about 90 minutes, followed by administering the oxaliplatin, followed by administering the leucovorin, followed by administering the 5-fluorouracil.

14. The method of claim 1 , wherein the liposomal irinotecan comprises irinotecan sucrose octasulfate encapsulated in liposomes.

15. The method of claim 1 , wherein the liposomal irinotecan comprises phosphatidylcholine, cholesterol, and a polyethleneglycol-derivatized phosphatidyl-ethanolamine in the amount of approximately one polyethyleneglycol (PEG) molecule for 200 phospholipid molecules.

16. The method of claim 15 , wherein the liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin are administered on days 1 and 15 of a 28-day treatment cycle; each administration of the liposomal irinotecan is administered prior to the leucovorin; the leucovorin is administered immediately prior to each administration of the 5-fluorouracil, and each administration of 5-fluorouracil is administered as an infusion over 46 hours.

17. The method of claim 15 , wherein the liposomal irinotecan comprises irinotecan sucrose octasulfate 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and a N-(carbonylmethoxypolyethlyene glycol-2000)-1,2-distearoly-sn-glycero-3-phosphoethanolamine (MPEG-2000-DSPE).

18. A method of treating gastric cancer in a human patient who has not previously received gemcitabine to treat the gastric cancer, the method comprising administering an antineoplastic therapy to the patient once every two weeks, the antineoplastic therapy consisting of:
a) 50 mg/m 2 ±5% of liposomal irinotecan,
b) 85 mg/m 2 ±5% oxaliplatin,
c) 200 mg/m 2 of the (l)-form of leucovorin or 400 mg/m 2 of the (l+d) racemic form of leucovorin, and
d) 2,400 mg/m 2 5-fluorouracil;
to treat the gastric cancer in the human patient.

19. A method of treating gastric cancer in a human patient who has not previously received gemcitabine to treat the gastric cancer, the method comprising administering an antineoplastic therapy to the patient once every two weeks, the antineoplastic therapy consisting of:
a) 55 mg/m 2 ±5% of liposomal irinotecan,
b) 60 mg/m 2 ±5% oxaliplatin,
c) 200 mg/m 2 of the (l)-form of leucovorin or 400 mg/m 2 of the (l+d) racemic form of leucovorin, and
d) 2,400 mg/m 2 5-fluorouracil;
to treat the gastric cancer in the human patient.

20. The method of claim 18 , wherein
a) the liposomal irinotecan comprises irinotecan sucrose octasulfate, phosphatidylcholine, cholesterol, and a polyethleneglycol-derivatized phosphatidyl-ethanolamine in the amount of approximately one polyethyleneglycol (PEG) molecule for 200 phospholipid molecules;
b) the liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin are administered on days 1 and 15 of a 28-day treatment cycle;
c) each administration of the liposomal irinotecan is administered prior to the leucovorin;
d) the leucovorin is administered immediately prior to each administration of the 5-fluorouracil;
e) each administration of 5-fluorouracil is administered as an infusion over 46 hours;
f) each administration of the oxaliplatin begins after completing each administration of the liposomal irinotecan; and
g) optionally administering a corticosteroid and anti-emetic to the patient prior to the antineoplastic therapy.

21. The method of claim 19 , wherein
a) the liposomal irinotecan comprises irinotecan sucrose octasulfate, phosphatidylcholine, cholesterol, and a polyethleneglycol-derivatized phosphatidyl-ethanolamine in the amount of approximately one polyethyleneglycol (PEG) molecule for 200 phospholipid molecules;
b) the liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin are administered on days 1 and 15 of a 28-day treatment cycle;
c) each administration of the liposomal irinotecan is administered prior to the leucovorin;
d) the leucovorin is administered immediately prior to each administration of the 5-fluorouracil;
e) each administration of 5-fluorouracil is administered as an infusion over 46 hours;
f) each administration of the oxaliplatin begins after completing each administration of the liposomal irinotecan; and
g) optionally administering a corticosteroid and anti-emetic to the patient prior to the antineoplastic therapy.

Assignees

• Ipsen Biopharm Ltd

Inventors

• Fitzgerald Jonathan Basil
• Kalra Ashish
• Leonard Shannon
• Braun Stephan
• Zhang Bin

Classifications

• A61K33/243

  Platinum; Compounds thereof · CPC title

• A61K31/513

  having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title

• A61K31/4453

  only substituted in position 1, e.g. propipocaine, diperodon · CPC title

• A61K31/437 Primary

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• A61K31/4178

  not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin · CPC title